Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma

Suzanne Trudel, Scott Ely, Yildiz Farooqi, Maurizio Affer, Davide F. Robbiani, Marta Chesi, Peter Leif Bergsagel

Research output: Contribution to journalArticle

139 Citations (Scopus)

Abstract

We have previously shown that dysregulation of fibroblast growth factor receptor 3 (FGFR3) by the t(4;14) translocation is a primary event in multiple myeloma (MM) and that activating mutations of FGFR3 are acquired in some cases. We describe here inhibition of wild-type (WT) and constitutively activated mutant FGFR3 autophosphorylation by the small molecule inhibitor, PD173074. Inhibition of FGFR3 in human myeloma cell lines was associated with decreased viability and tumor cell growth arrest. Further, morphologic, phenotypic, and functional changes typical of plasma cell (PC) differentiation, including increase in light-chain secretion and expression of CD31, were observed and this was followed by apoptosis. Finally, using a mouse model of FGFR3 myeloma, we demonstrate a delay in tumor progression and prolonged survival of mice treated with PD173074. These results indicate that inhibition of FGFR3, even in advanced disease associated with multiple genetic changes, may allow the cell to complete its developmental program and render it sensitive to apoptotic signals. In addition, this represents the validation of a therapeutic target in MM that may benefit patients who have a very poor prognosis with currently available treatments.

Original languageEnglish (US)
Pages (from-to)3521-3528
Number of pages8
JournalBlood
Volume103
Issue number9
DOIs
StatePublished - May 1 2004
Externally publishedYes

Fingerprint

Receptor, Fibroblast Growth Factor, Type 3
Apoptosis
Multiple Myeloma
Tumors
Plasma Cells
Cell growth
Cell Differentiation
Neoplasms
Cell Survival
Light
Cell Line
Cells
Mutation
Plasmas
Therapeutics
Growth
Molecules

ASJC Scopus subject areas

  • Hematology

Cite this

Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma. / Trudel, Suzanne; Ely, Scott; Farooqi, Yildiz; Affer, Maurizio; Robbiani, Davide F.; Chesi, Marta; Bergsagel, Peter Leif.

In: Blood, Vol. 103, No. 9, 01.05.2004, p. 3521-3528.

Research output: Contribution to journalArticle

Trudel, Suzanne ; Ely, Scott ; Farooqi, Yildiz ; Affer, Maurizio ; Robbiani, Davide F. ; Chesi, Marta ; Bergsagel, Peter Leif. / Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma. In: Blood. 2004 ; Vol. 103, No. 9. pp. 3521-3528.
@article{fb2ecc3e943045b39cfbd7bc105d0a2e,
title = "Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma",
abstract = "We have previously shown that dysregulation of fibroblast growth factor receptor 3 (FGFR3) by the t(4;14) translocation is a primary event in multiple myeloma (MM) and that activating mutations of FGFR3 are acquired in some cases. We describe here inhibition of wild-type (WT) and constitutively activated mutant FGFR3 autophosphorylation by the small molecule inhibitor, PD173074. Inhibition of FGFR3 in human myeloma cell lines was associated with decreased viability and tumor cell growth arrest. Further, morphologic, phenotypic, and functional changes typical of plasma cell (PC) differentiation, including increase in light-chain secretion and expression of CD31, were observed and this was followed by apoptosis. Finally, using a mouse model of FGFR3 myeloma, we demonstrate a delay in tumor progression and prolonged survival of mice treated with PD173074. These results indicate that inhibition of FGFR3, even in advanced disease associated with multiple genetic changes, may allow the cell to complete its developmental program and render it sensitive to apoptotic signals. In addition, this represents the validation of a therapeutic target in MM that may benefit patients who have a very poor prognosis with currently available treatments.",
author = "Suzanne Trudel and Scott Ely and Yildiz Farooqi and Maurizio Affer and Robbiani, {Davide F.} and Marta Chesi and Bergsagel, {Peter Leif}",
year = "2004",
month = "5",
day = "1",
doi = "10.1182/blood-2003-10-3650",
language = "English (US)",
volume = "103",
pages = "3521--3528",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "9",

}

TY - JOUR

T1 - Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma

AU - Trudel, Suzanne

AU - Ely, Scott

AU - Farooqi, Yildiz

AU - Affer, Maurizio

AU - Robbiani, Davide F.

AU - Chesi, Marta

AU - Bergsagel, Peter Leif

PY - 2004/5/1

Y1 - 2004/5/1

N2 - We have previously shown that dysregulation of fibroblast growth factor receptor 3 (FGFR3) by the t(4;14) translocation is a primary event in multiple myeloma (MM) and that activating mutations of FGFR3 are acquired in some cases. We describe here inhibition of wild-type (WT) and constitutively activated mutant FGFR3 autophosphorylation by the small molecule inhibitor, PD173074. Inhibition of FGFR3 in human myeloma cell lines was associated with decreased viability and tumor cell growth arrest. Further, morphologic, phenotypic, and functional changes typical of plasma cell (PC) differentiation, including increase in light-chain secretion and expression of CD31, were observed and this was followed by apoptosis. Finally, using a mouse model of FGFR3 myeloma, we demonstrate a delay in tumor progression and prolonged survival of mice treated with PD173074. These results indicate that inhibition of FGFR3, even in advanced disease associated with multiple genetic changes, may allow the cell to complete its developmental program and render it sensitive to apoptotic signals. In addition, this represents the validation of a therapeutic target in MM that may benefit patients who have a very poor prognosis with currently available treatments.

AB - We have previously shown that dysregulation of fibroblast growth factor receptor 3 (FGFR3) by the t(4;14) translocation is a primary event in multiple myeloma (MM) and that activating mutations of FGFR3 are acquired in some cases. We describe here inhibition of wild-type (WT) and constitutively activated mutant FGFR3 autophosphorylation by the small molecule inhibitor, PD173074. Inhibition of FGFR3 in human myeloma cell lines was associated with decreased viability and tumor cell growth arrest. Further, morphologic, phenotypic, and functional changes typical of plasma cell (PC) differentiation, including increase in light-chain secretion and expression of CD31, were observed and this was followed by apoptosis. Finally, using a mouse model of FGFR3 myeloma, we demonstrate a delay in tumor progression and prolonged survival of mice treated with PD173074. These results indicate that inhibition of FGFR3, even in advanced disease associated with multiple genetic changes, may allow the cell to complete its developmental program and render it sensitive to apoptotic signals. In addition, this represents the validation of a therapeutic target in MM that may benefit patients who have a very poor prognosis with currently available treatments.

UR - http://www.scopus.com/inward/record.url?scp=1942456800&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1942456800&partnerID=8YFLogxK

U2 - 10.1182/blood-2003-10-3650

DO - 10.1182/blood-2003-10-3650

M3 - Article

C2 - 14715624

AN - SCOPUS:1942456800

VL - 103

SP - 3521

EP - 3528

JO - Blood

JF - Blood

SN - 0006-4971

IS - 9

ER -